Correlates of obesity-related chronic ventilatory failure

Ari R Manuel,1 Nicholas Hart,2 John R Stradling1

ABSTRACT

Introduction: Only a third of obese patients develop chronic ventilatory failure. This cross-sectional study assessed multiple factors potentially associated with chronic ventilatory failure.

Materials/patients and methods: Participants had a body mass index (BMI) >30 kg/m2, with or without chronic ventilatory failure (awake arterial partial pressure of carbon dioxide >6 kPa or base excess (BE) ≥2 mmols/L). Factors investigated were grouped into domains: (1) obesity measures, (2) pulmonary function, (3) respiratory and non-respiratory muscle strength, (4) sleep study derivatives, (5) hypoxic and hypercapnic responses, and (6) some hormonal, nutritional and inflammatory measures.

Results: 71 obese participants (52% male) were studied over 27 months, 52 (SD 9) years and BMI 47 (range 32–74) kg/m2. The best univariate correlates of BE from each domain were: (1) dual-energy X-ray absorptiometry measurement of visceral fat (r=+0.50, p=0.001); (2) supine forced expiratory volume in 1 s (r=−0.40, p=0.001); (3) sniff maximum pressure (r=−0.28, p=0.02); (4) mean overnight arterial oxygen saturation (r=−0.50, p<0.001); (5) ventilatory response to 15% O2 breathing (r=−0.28, p=0.02); and (6) vitamin D (r=−0.30, p=0.01). In multivariate analysis, only visceral fat and ventilatory response to hypoxia remained significant.

Conclusions: We have confirmed that in the obese, BMI is a poor correlate of chronic ventilatory failure, and the best independent correlates are visceral fat and hypoxic ventilatory response.

Trial registration number: NCT01380418.

INTRODUCTION

Patients with obesity-related chronic ventilatory failure have higher morbidity, mortality and healthcare utilisation, compared with eucapnic obese participants.1 The clinical features of obesity (body mass index, BMI >30 kg/m2), and daytime hypercapnia (arterial partial pressure of carbon dioxide, PaCO2 >6 kPa), in the absence of any other discernible cause, define obesity hypoventilation syndrome (OHS), while some also include the presence of sleep-disordered breathing (SDB) in the definition.2 Only a third of patients with obesity develop chronic ventilatory failure,3 and the reasons for this are poorly understood. We have prospectively measured a wide range of factors potentially impacting on ventilatory failure in a cross-sectional study of obese participants, with and without chronic ventilatory failure, in order to rank the possible key respiratory and non-respiratory factors associated with the presence of chronic ventilatory failure.

METHODS

Study design and setting

This was an open, cross-sectional study of obese participants, with and without chronic ventilatory failure, carried out between June 2011 and September 2013 in the Oxford Sleep Unit, Churchill Hospital, UK. An earlier article based on this group of patients, demonstrating that an isolated raised base excess (BE) is part of the spectrum of OHS, has already been published.4 Further details of the methods can be found in the online supplementary data. The study was approved by the Oxford Research Ethics Committee (Oxfordshire REC B 11/H0605/9) and pre-registered (ClinicalTrials.gov Identifier: NCT01380418).

Participants

A random sample of obese participants (BMI >30 kg/m2) with or without chronic ventilatory failure were recruited following referral to the sleep and ventilation clinic, or during...
assessment for possible bariatric surgery. Participants were excluded if: currently on drugs potentially stimulat-
ing/depressing respiration, diuretics, or theophylline; had obstructive lung disease (forced expiratory volume in 1 s (FEV₁)/forced vital capacity (FVC) ratio <70% predicted); had other severe comorbidities, for example, congestive cardiac failure, primary central nervous system or neuromuscular diseases, and untreated hypo-
hyroidism; or were currently on treatment with continu-
ous positive airways pressure or non-invasive ventilation. No patients were recruited who had a respiratory illness during the previous 4 weeks.

In addition to basic and demographic information, six potential respiratory and non-respiratory mechanistic domains that could contribute to chronic ventilatory failure were assessed: obesity and its distribution; lung function; respiratory and non-respiratory muscle strength; sleep-related measures; ventilatory response; and hormonal, nutritional and inflammatory measures.

**Basic and demographic data**

Age, sex, height, weight, BMI, resting arterial oxygen saturation (SpO₂), and daytime somnolence (Epworth Sleepiness Score (ESS)) were measured. Venous blood and radial arterial blood (breathing air) were sampled with participants in a seated position between 8:00 and 10:00, after at least 15 min rest. Oxygen tension (arterial partial pressure of oxygen, PaO₂), carbon dioxide tension (PaCO₂), pH, standard bicarbonate concentration and BE were measured on an analyser maintained and calibrated according to the manufacturer’s recommenda-
tions (ABL 90, Radiometer, West Sussex, UK).

**Measures of obesity and its distribution**

Body fat and its distribution were assessed in several ways: waist (cm), hip (cm), neck (cm), dual-energy X-ray absorptiometry (DXA), including the estimated visceral adipose tissue component in the android region; Lunar, GE Healthcare, Chalfont St Giles, UK), and bioimpe-
dance (Bodystat 1500 analyser, Bodystat Ltd, Douglas, Isle of Man, UK). An estimation of visceral adipose tissue by DXA was only available from participants with a BMI ≤40; the algorithm estimating visceral fat, which essentially subtracts cutaneous fat from the overall abdominal fat, has not been verified beyond this level of obesity. """"

**Lung function**

Lung function was measured sitting and supine: FEV₁, FVC, FEV₁/FVC ratio, relaxed vital capacity and expira-
tory reserve volume.

**Muscle strength**

Respiratory muscle strength was assessed seated from pressures (cm H₂O) at the mouth: maximum inspiratory pressure (MIP) after maximal expiration at residual volume, maximal expiratory pressure after maximal inspiration, at total lung capacity (MicroRPM, CareFusion, Basingstoke, UK); and sniff nasal inspiratory pressures at functional residual capacity, during five maximal sniffs, in a standardised manner as previously described. """" Non-respiratory muscle strength was also assessed.

**Sleep-related measures**

SDB was assessed from a one-night, in-hospital, respira-
tory polygraphic sleep study (Win-Visi monitoring system; Stowood Scientific Instruments, Oxford, UK).

**Ventilatory responses**

Two-point ventilatory responses were measured to hypoxia (15% O₂, poikilocapnic) and hypercapnia (5% CO₂, balance O₂).

**Hormonal, nutritional and inflammatory measures**

Several hormonal, nutritional and inflammatory vari-
ables were measured, potentially related to muscle weak-
ness and poor diet: fasting glucose and insulin, glycated haemoglobin, vitamin D, brain natriuretic peptide, iron studies, vitamin B₁₂, folate, fatty acids, thyroid-stimulating hormone, leptin, adiponectin and C reactive protein. Fasting blood samples were taken in the morning following the overnight sleep study.

Further information on some of the methods is con-
tained in the online supplementary data.

**Statistical methods**

Data analyses were performed using SPSS (V.22, IBM Corporation Ltd, USA). Data were tested for normality and presented as the mean and SD unless otherwise indicated. Statistical analysis for the potential correlates of ventilatory failure was a two-stage process. First, within each mechanistic domain, Pearson’s analysis was used to find the measures that most correlated with the degree of ventilatory failure (using both arterial CO₂ and BE). Then the best independent representatives of each mechanistic domain, most likely to be causal rather than simply reflecting the degree of ventilatory failure, were entered into a final forward stepwise multiple regression analysis to identify the overall ranking of independent correlates of ventilatory failure. All data were collected from all patients apart from the quadriceps muscle strength, which was performed on only the last 40 patients due to late availability of the equipment. The measurement of visceral adipose tissue by DXA was only available from participants with a BMI ≤40, as the algo-

**RESULTS**

Seventy-one obese participants (52% male) were studied. Forty-one obese participants were referred from the bariatric service (60% female; BMI 48.1) and 30 par-
ticipants from the sleep and ventilation clinic (55% male; BMI 45.3). Table 1 shows the arterial blood gas data.
Individual domain analyses

Measures of obesity and its distribution

Table 2 shows the stronger correlations between chronic ventilatory failure (BE and PaCO2) and age, and the measures of obesity and its distribution. BMI correlated poorly with chronic ventilatory failure defined either by PaCO2 or BE (r=0.21, p=NS; r=0.20, p=NS, respectively). The strongest correlation was with the DXA measurements of visceral fat (BE, r=0.50; p=0.001), although these were only available from the 43 participants with a BMI ≤40 kg/m2. Neck circumference and the impedance measure were significantly correlated with either PaCO2 or BE (r=−0.28, p=0.02, r=−0.27, p=0.03, respectively), albeit the relationships were weaker. There were no other correlates between the measures of obesity and chronic ventilatory failure.

Lung function

Online supplementary table S1 shows the stronger correlations between ventilatory failure and measures of lung function. Supine FEV1 had the strongest correlation with muscle strength. The maximum sniff pressure was the strongest correlate of the BE (r=−0.28, p=0.02), although the MIP approached significance (r=−0.22, p=0.06). There were no other significant correlations with non-respiratory muscle strength measures.

Sleep-related measures

Online supplementary table S3 shows the stronger correlations between chronic ventilatory failure and the sleep study derivatives. The measures of overall nocturnal hypoxia (mean overnight %SaO2, and the %time below 90% SaO2) were the strongest correlates of chronic ventilatory failure (BE, r=−0.50, p<0.001 and r=+0.46, p<0.001, respectively). The oxygen desaturation index (ODI) was also correlated (BE, r=+0.34, p=0.004), but there was no correlation with the apnoea hypopnoea index.

Hypoxic and hypercapnic ventilatory response

Online supplementary tables S4 and S5 show the stronger correlations between chronic ventilatory failure and the baseline ventilation measurements, the ventilatory response to breathing 15% oxygen and to 5% CO2 in oxygen. The poikilocapnic ventilatory response to hypoxia was significantly correlated with the BE (r=−0.28, p=0.02). The fall in SaO2 during 15% O2 breathing was actually the most correlated with BE (r=+0.46, p<0.001), but part of this measure will depend on the baseline PaCO2 and PaO2 themselves.

Hormonal, nutritional, and inflammatory measures

Online supplementary table S6 shows the stronger correlations between ventilatory failure and various hormonal, nutritional and inflammatory measures. Vitamin D levels inversely correlated with BE (r=−0.3, p=0.01) and were generally low, with 19% having levels which are classified as severely deficient (<12.5 nmol/L).9 10 There were only two other significant correlates: BNP and transferrin. Iron in serum is mainly transported by transferrin.11 All but one BNP level (102 ng/mL) were below the usual threshold to define heart failure (100 ng/mL).

Table 2

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean (SD)</th>
<th>Range (0–100%)</th>
<th>Correlation to BE (p value)</th>
<th>Correlation to PaCO2 (p value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>52.0 (8.9)</td>
<td>26–74</td>
<td>+0.06 (0.63)</td>
<td>+0.17 (0.17)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>136.3 (29.5)</td>
<td>77.8–229</td>
<td>+0.19 (0.11)</td>
<td>+0.18 (0.13)</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>47.2 (9.8)</td>
<td>32.3–73.9</td>
<td>+0.20 (0.09)</td>
<td>+0.21 (0.08)</td>
</tr>
<tr>
<td>Neck (cm)</td>
<td>46.5 (4.8)</td>
<td>38–58</td>
<td>+0.15 (0.22)</td>
<td>+0.28 (0.02)</td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>134.8 (20.9)</td>
<td>102–180</td>
<td>+0.21 (0.08)</td>
<td>+0.22 (0.07)</td>
</tr>
<tr>
<td>Hip (cm)</td>
<td>133.9 (20.2)</td>
<td>101–177</td>
<td>+0.18 (0.13)</td>
<td>+0.18 (0.15)</td>
</tr>
<tr>
<td>Impedance (ohms)</td>
<td>382.3 (86.9)</td>
<td>194–704</td>
<td>−0.18 (0.15)</td>
<td>−0.27 (0.03)</td>
</tr>
<tr>
<td>Visceral adipose tissue mass (kg)</td>
<td>3.42 (1.17)</td>
<td>1.31–5.64</td>
<td>+0.50 (0.001)</td>
<td>+0.36 (0.02)</td>
</tr>
</tbody>
</table>

Mean (SD) for variables in the ‘distribution of fat’ domain, with range (0–100%). The obesity measures shown are those exhibiting the highest correlations with BE and PaCO2 (p values in brackets). There were no other significant correlations between obesity measures and either BE or PaCO2. Note, visceral adipose tissue estimates from DXA were only available for participants with BMI ≤40, n=43.
Regression analysis across all the respiratory and non-respiratory domains

The upper part of Table 3 shows the strongest significant independent correlates from each of the individual respiratory and non-respiratory domains that could be potentially causal. The lower part of Table 3 shows the result of the regression analysis of all these six factors. The only two significant factors associated with chronic ventilatory failure were the DXA measure of intra-abdominal (visceral) fat, and the poikilocapnic ventilatory response to breathing 15% oxygen. Vitamin D levels were the next most significant, but only reached a significance level of 0.19. All the other factors were not significant in the final model.

DISCUSSION

In this prospective, hypothesis-generating, observational cross-sectional study of a group of obese individuals, we have confirmed that BMI alone is a relatively poor correlate of ventilatory failure. Age was also not a significant correlate, implying it is not simply that it takes time for a given level of obesity to provoke ventilatory failure. There are a number of strong correlations in each of the biological domains, suggesting that ventilatory failure in obesity is likely to be multifactorial. However, the main independent correlations were the presence of intra-abdominal fat on DXA scan, and a reduction in the ventilatory response to 15% oxygen.

It might be argued that, due to the shape of the haemoglobin dissociation curve, the ventilatory response, and the absolute fall in SaO2, during 15% O2 breathing would be expected to be greater if initially more hypoxic, and therefore already on the steeper part of the curve. This would be true to some extent for the absolute SaO2 fall during 15% oxygen breathing. However, while it is accepted that the physiological response to hypoxia is dependent on numerous factors, the ventilatory response to hypoxia has been shown to be rendered linear when plotted against SaO2, thus the slope of the ventilatory response to hypoxia (ΔV/Δ% SaO2) should not depend on where one starts on the dissociation curve. Furthermore, the change in minute ventilation during the 15% O2 challenge test was also correlated with the BE, which would not be expected if the reduced ventilatory response was simply the result of the initial position on the dissociation curve.

Other studies have also shown that patients with OHS have a reduced ventilatory response to hypoxia, failure to maintain ventilation in the face of nocturnal hypoventilation is a plausible contributory cause to the development of diurnal hypoventilation. The extra nocturnal hypoventilation seen in obese individuals is presumably provoked by some other factor, with the reduced hypoxic ventilatory response playing a permissive role. Removal of carotid bodies in humans and animals reduces hypoxic drive and leads to a gradual development of chronic ventilatory failure. Repeated periods of extranight hypoventilation will lead to renal bicarbonate retention that may not be fully cleared during waking hours, leading to a gradual increase over time, with the alkalosis-suppressing awake ventilation. This was the explanation advanced by Berger et al. and modelled by Norman et al.

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Linear regression analysis using the best independent correlates of BE from each domain</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Best independent correlates from each domain</strong></td>
<td><strong>Correlation coefficient</strong></td>
</tr>
<tr>
<td>Obesity</td>
<td></td>
</tr>
<tr>
<td>Visceral adipose tissue volume by DXA scan</td>
<td>+0.50</td>
</tr>
<tr>
<td>Lung function</td>
<td></td>
</tr>
<tr>
<td>FEV1%, supine</td>
<td>−0.40</td>
</tr>
<tr>
<td>Sleep variables</td>
<td></td>
</tr>
<tr>
<td>Mean overnight oxygen saturation</td>
<td>−0.50</td>
</tr>
<tr>
<td>Ventilatory control</td>
<td></td>
</tr>
<tr>
<td>Ventilatory response to 15% oxygen</td>
<td>−0.28</td>
</tr>
<tr>
<td>Respiratory muscle strength</td>
<td></td>
</tr>
<tr>
<td>Sniff maximum (cm H2O)</td>
<td>−0.28</td>
</tr>
<tr>
<td>Hormonal, nutritional and inflammatory measures</td>
<td></td>
</tr>
<tr>
<td>Vitamin D</td>
<td>−0.30</td>
</tr>
<tr>
<td>ventilation</td>
<td></td>
</tr>
<tr>
<td>Cumulative correlation coefficient</td>
<td></td>
</tr>
<tr>
<td><strong>Significant independent correlates</strong></td>
<td><strong>Correlation coefficient</strong></td>
</tr>
<tr>
<td>Visceral adipose tissue volume by DXA scan</td>
<td>+0.49</td>
</tr>
<tr>
<td>Ventilatory response to 15% oxygen</td>
<td>+0.58</td>
</tr>
</tbody>
</table>

Results for the best correlates of BE in a linear regression for each individual domain. The correlate was chosen on the basis of the likelihood of it having a causal association with BE (eg, ventilatory response to 15% oxygen was chosen over the absolute fall in SaO2 and vitamin D was chosen over both BNP and transferrin). The lower part of the table shows the result for the best overall significant independent correlates of BE in a multiple linear regression containing the best correlate from each domain. A cumulative correlation coefficient of 0.58 indicates that the model accounts for 34% of the variance in BE. Vitamin D levels were the next most significant correlate, but with a p value of 0.19. BE, base excess; BNP, brain natriuretic peptide; DXA, dual-energy X-ray absorptiometry; FEV1, forced expiratory volume in 1 s.
Alternatively, the chronic hypoxia of OHS may have blunt the ventilatory response to hypoxaemia. There is inconsistent evidence for a reduced ventilatory drive to hypoxia following, for example, long-term exposure to altitude in lowlanders. However, even if acquired blunting is the explanation in our patients, it would still imply that restoration of ventilatory drive should be considered as a therapeutic target.

Finally, it may be that the blunted hypoxic response in our patients was simply due to the mechanical fat load, although we think this unlikely for three reasons: those with eucapnia, but an isolated bicarbonate retention, had been able to return their PaCO2 to normal during the day, yet still exhibited a reduced hypoxic ventilatory response, there were patients in our cross-sectional with normal lung volumes and muscle strength who exhibited reduced hypoxic response, but normal hypercapnic responses; and there was very little correlation between hypoxic and hypercapnic responses (r=0.08, p=0.53), which one would have expected if they were dominantly impaired by pump overload.

Preferential abdominal obesity is a plausible contributory cause to the gradual development of daytime hypercapnia. A cross-sectional population-based study including nearly 122 000 participants showed that abdominal obesity was the strongest correlate of impaired lung function and early work in this area identified a reduced expiratory reserve volume as a possible provoker of obesity-related hypventilation.

Using a wide range of body fat variables (including DXA to determine the effect of fat distribution on lung volumes), found in healthy adults that lung volumes were only loosely associated with BMI. Variables derived from both DXA and non-DXA measurements, reflecting upper body fat, had highly significant negative correlations with functional residual capacity and expiratory reserve volume in both men and women.

Our findings, albeit within the BMI range 30–40, suggest that more fat, actually inside the abdominal cavity, may be especially important. Particularly on lying down, the weight of abdominal fat will restrict the descent of the diaphragm; this will also narrow small airways with an increase in airflow resistance and intrinsic positive end expiratory pressure.

The diaphragm may even be overstretched, reducing muscle fibre contraction efficiency. This effect of a raised intra-abdominal pressure on ventilation is well recognised in individuals with other pathologies that raise intra-abdominal pressure (particularly seen in acutely ill patients in intensive care), additional obesity is a significant extra risk factor for ventilatory failure.

It may be that intra-abdominal fat is more significant than subcutaneous abdominal wall fat at embarrassing the diaphragm when abdominal compartment expansion is limited, and thus effectively under pressure. However, more data are required at higher obesity levels over a BMI of 40.

An interesting observation in our data set was that neck circumference was a better correlate of DXA visceral fat (r=+0.66, p<0.001) than either waist circumference (r=+0.27, p=0.10) or waist/hip ratio (r=+0.19, p=0.24). This underlines the problem that obstructive sleep apnoea (OSA) may indirectly code for the metabolic syndrome in cross-sectional studies seeking to explore the relationship between OSA and cardiovascular consequences.

Interpreting the sleep data correlates of ventilatory failure as possible evidence for any primary causal role is also difficult. Lower nocturnal saturations may reflect combinations of an initially lower starting SaO2, nocturnal hypoventilation secondary to abdominal fat loading, poor hypoxic drive permissive of yet further hypoventilation, all of which will lead eventually to bicarbonate retention and diurnal ventilatory failure. There was no suggestion within these data that the presence of OSA (measured either as the apnoea/hypopnoea index or ODI) was contributory.

Nearly 20% of the patients in our study were severely deficient in vitamin D, possibly contributing to a low-grade proximal myopathy, thus, a pilot trial of vitamin D replacement in those deficient might be appropriate. However, vitamin D levels did not significantly correlate with our measures of either ventilatory or non-ventilatory muscle strength. The explanation for higher transferrin levels correlating with worse ventilatory failure is not clear. Higher transferrin levels would normally suggest iron deficiency, but no other iron status measure corroborated this. Isolated raised transferrin can occur with raised oestrogen levels that are also found in the obese.

None of our patients had clinically detectable heart failure, and this was confirmed by the essentially normal BNP levels. The strong correlation between BNP levels (albeit within the normal range) and the markers of ventilatory failure is likely to be a result rather than a cause. Reduced oxygen tensions are an independent factor regulating the synthesis and release of natriuretic peptides, and hypoxia response elements have also been found in the promoter sequence of the human BNP gene.

A significant limitation to this study was that the estimation of visceral adipose tissue by DXA was not available from participants with a BMI >40, as the relevant algorithms have not been verified beyond this level of obesity. Thus, it is possible that this relationship might not continue to be true for BMI values above 40. However, it is encouraging that the relationship did exist, even within the relatively narrow range of BMI values (30–40).

Our work suggests that reversing the gradual accumulation of bicarbonate may be an alternative strategy in managing obesity hypoventilation. This has not been considered safe in most other examples of hypercapnic ventilatory failure, where the respiratory pump is failing or overwhelmed, such as neuromuscular disease or...
severe chronic obstructive lung disease, when increasing ventilatory drive is likely to be ineffective and potentially dangerous. Thus, it would seem reasonable to perform a randomised controlled trial of acetazolamide, or equivalent, in patients with obesity hypoventilation, who are not in acute decompensation, despite this not being currently recommended. There are already small uncontrolled trials of acetazolamide in obesity looking at hypercapnic drive and nocturnal hypoxia that are suggestive of improvement in patients with central sleep apnoea.

Acknowledgements

Many thanks and appreciation to Richard Madgewick for his help with lung function and ventilatory drive measurements and Debby Nichols and Barbara Winter for their help with the sleep measurements of the study.

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.

Competing interests

Philips-Respironics, UK.

Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by the Oxford NIHR Biomedical Research Centre, and the Oxford Centre, the Oxford NIHR Biomedical Research Centre, and the Oxford

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.

Competing interests

Philips-Respironics, UK.

Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by the Oxford NIHR Biomedical Research Centre, and the Oxford

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.

Competing interests

Philips-Respironics, UK.

Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by the Oxford NIHR Biomedical Research Centre, and the Oxford

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.

Competing interests

Philips-Respironics, UK.

Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by the Oxford NIHR Biomedical Research Centre, and the Oxford

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.

Competing interests

Philips-Respironics, UK.

Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by the Oxford NIHR Biomedical Research Centre, and the Oxford

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.

Competing interests

Philips-Respironics, UK.

Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by the Oxford NIHR Biomedical Research Centre, and the Oxford

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.

Competing interests

Philips-Respironics, UK.

Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by the Oxford NIHR Biomedical Research Centre, and the Oxford

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.

Competing interests

Philips-Respironics, UK.

Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by the Oxford NIHR Biomedical Research Centre, and the Oxford

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.

Competing interests

Philips-Respironics, UK.

Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by the Oxford NIHR Biomedical Research Centre, and the Oxford

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.

Competing interests

Philips-Respironics, UK.

Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by the Oxford NIHR Biomedical Research Centre, and the Oxford

Funding

This work was supported by the Oxford Health Services Research Committee, the Oxford NIHR Biomedical Research Centre, and the Oxford Radcliffe Hospital Charitable Funds. The NICO 2 device was kindly donated by Philips-Respironics, UK.

Competing interests

None declared.

Ethics approval

Oxfordshire REC B 11/H0605/9.

Data sharing statement

Oxfordshire REC B 11/H0605/9.

None declared.